Arbutus Biopharma (ABUS)
(Delayed Data from NSDQ)
$2.73 USD
+0.01 (0.37%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $2.72 -0.01 (-0.37%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Balance Sheet
Fiscal Year End for Arbutus Biopharma Corporation falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 126 | 147 | 155 | 123 | 91 |
Receivables | 2 | 1 | 1 | 1 | 1 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 4 | 3 | 4 | 3 | 2 |
Total Current Assets | 132 | 151 | 161 | 128 | 94 |
Net Property & Equipment | 5 | 5 | 6 | 7 | 9 |
Investments & Advances | 6 | 37 | 36 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 144 | 195 | 204 | 137 | 106 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 10 | 16 | 11 | 9 | 7 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 12 | 16 | 0 | 0 | 0 |
Total Current Liabilities | 22 | 33 | 11 | 10 | 8 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 6 | 0 | 0 | 0 |
Other Non-Current Liabilities | 15 | 18 | 22 | 23 | 22 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 38 | 59 | 35 | 35 | 33 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 149 | 137 |
Common Stock (Par) | 1,350 | 1,319 | 1,287 | 986 | 899 |
Capital Surplus | 81 | 72 | 65 | 61 | 55 |
Retained Earnings | -1,277 | -1,204 | -1,134 | -1,046 | -970 |
Other Equity | -48 | -50 | -48 | -48 | -48 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 106 | 137 | 169 | 102 | 73 |
Total Liabilities & Shareholder's Equity | 144 | 195 | 204 | 137 | 106 |
Total Common Equity | 106 | 137 | 169 | -47 | -65 |
Shares Outstanding | 167.70 | 149.90 | 144.90 | 89.60 | 64.70 |
Book Value Per Share | 0.63 | 0.91 | 1.17 | -0.53 | -1.00 |
Fiscal Year End for Arbutus Biopharma Corporation falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 126 | 134 | 152 | 147 |
Receivables | NA | 2 | 2 | 3 | 3 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 4 | 5 | 4 | 3 |
Total Current Assets | NA | 132 | 142 | 159 | 153 |
Net Property & Equipment | NA | 5 | 5 | 5 | 5 |
Investments & Advances | NA | 6 | 11 | 11 | 32 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 0 | 0 | 0 | 0 |
Total Assets | NA | 144 | 159 | 177 | 191 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 10 | 10 | 9 | 10 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 0 | 0 | 0 | 0 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 12 | 12 | 15 | 15 |
Total Current Liabilities | NA | 22 | 22 | 25 | 25 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 3 |
Other Non-Current Liabilities | NA | 15 | 16 | 17 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 38 | 39 | 42 | 47 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 1,350 | 1,346 | 1,344 | 1,339 |
Capital Surplus | NA | 81 | 80 | 77 | 74 |
Retained Earnings | NA | -1,277 | -1,257 | -1,237 | -1,220 |
Other Equity | NA | -48 | -49 | -49 | -50 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 106 | 119 | 135 | 144 |
Total Liabilities & Shareholder's Equity | NA | 144 | 159 | 177 | 191 |
Total Common Equity | 0 | 106 | 119 | 135 | 144 |
Shares Outstanding | 179.40 | 167.70 | 167.70 | 166.90 | 165.10 |
Book Value Per Share | 0.00 | 0.63 | 0.71 | 0.81 | 0.87 |